/

Sociétés

Ge

Non vérifié

Genentech

Ce que nous écrivons

BiotechnologieIndustrieIndustrie pharmaceutiqueMédecine - DiversSanté

82 communiqués de presse

Voir tous les communiqués de presse

30/04/2026

Événements

Expos

Industrie

Science

Biotechnologie

Industrie pharmaceutique

Optique

Santé Publique

Santé

Médecine - Divers

Genentech to Present Extensive Data Showcasing Its Industry-Leading Ophthalmology Portfolio at ARVO 2026

Source

Émetteur

1.00

0

24/04/2026

Genentech Partners With Comedy Icon Damon Wayans and diaTribe to Address Diabetes-Related Vision Loss With ‘All Eyes on DME’ Campaign

Source

Émetteur

1.00

0

21/04/2026

Événements

Industrie

Biotechnologie

Santé

Industrie pharmaceutique

Médecine - Divers

Genentech’s Fenebrutinib Significantly Reduced Relapses Versus Standard of Care to Approximately One Every 17 Years in RMS

Source

Émetteur

1.00

0

21/04/2026

Industrie

Santé

Médecine - Divers

Science

Industrie pharmaceutique

Biotechnologie

Genentech’s Enspryng (Satralizumab) Reduces Risk of Relapses by 68% Demonstrating Potential to Become First Treatment for MOGAD

Source

Émetteur

1.00

0

21/04/2026

Événements

Expos

Industrie

Santé

Hygiène alimentaire

Médecine - Divers

Science

Industrie pharmaceutique

Biotechnologie

CORRECTING and REPLACING FDA Accepts Application for Genentech’s Gazyva for the Treatment of the Most Common Form of Lupus

Source

Émetteur

1.00

0

21/04/2026

Événements

Expos

Industrie

Santé

Hygiène alimentaire

Médecine - Divers

Science

Industrie pharmaceutique

Biotechnologie

FDA Accepts Application for Genentech’s Gazyva for the Treatment of the Most Common Form of Lupus

Source

Émetteur

1.00

0

09/03/2026

Industrie

Science

Hygiène alimentaire

Médecine - Divers

Biotechnologie

Industrie pharmaceutique

Vitrines/Shopping

Santé

Oncologie

Genentech Provides Update on Phase III persevERA Study in ER-positive Advanced Breast Cancer

Source

Émetteur

1.00

0

06/03/2026

Industrie

Biotechnologie

Industrie pharmaceutique

Santé

Médecine - Divers

New England Journal of Medicine Publishes Phase III ALLEGORY Data Showing Genentech’s Gazyva Significantly Reduces Disease Activity in the Most Common Form of Lupus

Source

Émetteur

1.00

0

05/03/2026

Industrie

Santé

Médecine - Divers

Science

Industrie pharmaceutique

Biotechnologie

Genentech Announces Positive Phase II Results for Petrelintide, an Amylin Analog Developed for People Living With Overweight and Obesity

Source

Émetteur

1.00

0

02/03/2026

Industrie

Santé

Santé Publique

Médecine - Divers

Industrie pharmaceutique

Biotechnologie

Genentech's Fenebrutinib Confirms Its Potential as First and Only BTK Inhibitor for Relapsing and Primary Progressive MS in Third Positive Phase III Study (FENhance 1)

Source

Émetteur

1.00

0

Followers

0

Compatibilité

0